Cumberland Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Net Revenue Annually44.5MTarget: Double-digit annual revenue growth
Quarterly Net Revenue Quarterly9.1M
Cash and Cash Equivalents Quarterly11M
Watch Items
- Shareholder approval of the $100 million Apotex strategic transactionTrigger: Special Meeting vote on June 24, 2026Action: Monitor voting results and subsequent regulatory filings to confirm transaction closing.
- FDA approval progress for ifetroban in Duchenne muscular dystrophy (DMD)Trigger: Fast Track Designation granted; ongoing FDA discussions on Phase II cardiomyopathy resultsAction: Track regulatory milestones, clinical trial updates, and FDA feedback regarding approval requirements.
Research as of 20 Jun 2026